Unknown

Dataset Information

0

MicroRNA-29b inhibits diabetic nephropathy in db/db mice.


ABSTRACT: Inflammation and its consequent fibrosis are two main features of diabetic nephropathy (DN), but target therapy on these processes for DN remains yet ineffective. We report here that miR-29b is a novel therapeutic agent capable of inhibiting progressive renal inflammation and fibrosis in type 2 diabetes in db/db mice. Under diabetic conditions, miR-29b was largely downregulated in response to advanced glycation end (AGE) product, which was associated with upregulation of collagen matrix in mesangial cells via the transforming growth factor-? (TGF-?)/Smad3-dependent mechanism. These pathological changes were reversed by overexpressing miR-29b, but enhanced by knocking-down miR-29b. Similarly, loss of renal miR-29b was associated with progressive diabetic kidney injury, including microalbuminuria, renal fibrosis, and inflammation. Restored renal miR-29b by the ultrasound-based gene therapy was capable of attenuating diabetic kidney disease. Further studies revealed that inhibition of Sp1 expression, TGF-?/Smad3-dependent renal fibrosis, NF-?B-driven renal inflammation, and T-bet/Th1-mediated immune response may be mechanisms associated with miR-29b treatment in db/db mice. In conclusion, miR-29b may play a protective role in diabetic kidney disease and may have therapeutic potential for diabetic kidney complication.

SUBMITTER: Chen HY 

PROVIDER: S-EPMC3982502 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

MicroRNA-29b inhibits diabetic nephropathy in db/db mice.

Chen Hai-Yong HY   Zhong Xiang X   Huang Xiao R XR   Meng Xiao-Ming XM   You Yongke Y   Chung Arthur Ck AC   Lan Hui Y HY  

Molecular therapy : the journal of the American Society of Gene Therapy 20131206 4


Inflammation and its consequent fibrosis are two main features of diabetic nephropathy (DN), but target therapy on these processes for DN remains yet ineffective. We report here that miR-29b is a novel therapeutic agent capable of inhibiting progressive renal inflammation and fibrosis in type 2 diabetes in db/db mice. Under diabetic conditions, miR-29b was largely downregulated in response to advanced glycation end (AGE) product, which was associated with upregulation of collagen matrix in mesan  ...[more]

Similar Datasets

| S-EPMC4462147 | biostudies-other
| S-EPMC2451047 | biostudies-other
| S-EPMC4539432 | biostudies-literature
2004-01-20 | GSE710 | GEO
| S-EPMC3834765 | biostudies-literature
| S-EPMC6073714 | biostudies-literature
| S-EPMC10511534 | biostudies-literature
| S-EPMC3966238 | biostudies-literature
| S-EPMC8262660 | biostudies-literature
| S-EPMC5334541 | biostudies-literature